Abstract
Contact investigations are crucial for tuberculosis (TB) control, yet the temporal dynamics of disease progression among exposed contacts remain poorly understood. Here, we analyzed a retrospective cohort of 44,106 contacts of 6,243 TB cases identified through the Florida Department of Health surveillance system (2009-2023). During the 15-year follow-up period, 454 individuals within this cohort developed active TB disease. Using survival analysis and mixed-effect Cox proportional hazards models, we determined that the median time to TB disease onset was 11 months following the initial contact investigation. The risk of progression to TB disease varied markedly by age and immune status. Children aged 0-5 years showed nearly seven times higher risk of TB disease progression compared to adults 65 years and older (aHR = 6.66, 95% CI: 1.33-33.27). HIV-positive contacts demonstrated a five-fold increased risk (aHR = 4.75, 95% CI: 2.43-9.30) relative to HIV-negative individuals. These findings indicate that the risk of TB transmission and disease progression persists beyond initial contact investigation activities and varies significantly across demographic and clinical subgroups, suggesting the need for extended contact monitoring and age-specific preventive strategies, particularly for young children and immunocompromised individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received approval from the Institutional Review Board (IRB) at the University of Florida (approval number IRB201700445) and the Florida Department of Health (FDOH) TB Program. It was conducted as part of program evaluations and projects aimed at improving the clinical and public health services offered by state and local TB programs in Florida (SOW21-473 6.1.11). The approval authorities waived the requirement for informed consent, as the research used existing records and did not involve direct interaction with participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The dataset analyzed in this study includes sensitive patient information extracted from the Report of the Verified Case of Tuberculosis form. To protect patient privacy and maintain confidentiality, this dataset cannot be made publicly available. However, qualified researchers may access the dataset upon reasonable request, provided they adhere to appropriate data use agreements with the relevant institutional authorities that oversee the protection of this information thus the Institutional Review Board (IRB) at the Florida Department of Health (FDOH) TB Program.
